T1D, Metabolic Syndrome and Insulin Resistance

Sponsor
Universidad Juárez Autónoma de Tabasco (Other)
Overall Status
Completed
CT.gov ID
NCT05503303
Collaborator
(none)
19
1
7
2.7

Study Details

Study Description

Brief Summary

Patients with type 1 diabetes (T1D) and metabolic syndrome (MS) require high doses of insulin to achieve a glycemic control, due to insulin resistance (IR). The investigators identified the presence of metabolic syndrome and insulin resistance in patients with T1D in a population of southeast Mexico.

The sampled population was recruited from the Diabetes Clinic of the Regional Hospital of High Specialty "Dr. Gustavo A. Rovirosa Pérez"; from August 2021 to February 2022, graduated physicians interviewed patients previously diagnosed with T1D. This study included patients older than 18 years and at least six months after being diagnosed with T1D. The interviewers excluded patients who did not attend regular consultations and those who did not agree to participate or to give a blood sample. A diabetologist evaluated and diagnosed all patients based on the World Health Organization (WHO) criteria.

Fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols were determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics. The reasearch team determined glycated hemoglobin concentrations by an enzymatic immunoassay method.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    19 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    Clinical Characteristics in Adults With Type 1 Diabetes, Metabolic Syndrome and Insulin Resistance
    Actual Study Start Date :
    Aug 1, 2021
    Actual Primary Completion Date :
    Feb 15, 2022
    Actual Study Completion Date :
    Mar 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Glycated hemoglobin [March 2022]

      Concentrations by an enzymatic immunoassay method

    2. Total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols [March 2022]

      Determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 50 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • At least six months after being diagnosed with T1D
    Exclusion Criteria:
    • Did not attend regular consultations

    • Did not agree to participate or to give a blood sample

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Isela Esther Juarez Rojop Villahermosa Tabasco Mexico 86090

    Sponsors and Collaborators

    • Universidad Juárez Autónoma de Tabasco

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    ISELA ESTHER JUAREZ-ROJOP Ph.D., Full-Time Investigator Professor, Universidad Juárez Autónoma de Tabasco
    ClinicalTrials.gov Identifier:
    NCT05503303
    Other Study ID Numbers:
    • T1D-DACS2022
    First Posted:
    Aug 16, 2022
    Last Update Posted:
    Aug 19, 2022
    Last Verified:
    Aug 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 19, 2022